Gamida Cell Stock (NASDAQ:GMDA)
Previous Close
$0.04
52W Range
$0.03 - $2.51
50D Avg
$0.33
200D Avg
$0.77
Market Cap
$4.34M
Avg Vol (3M)
$9.38M
Beta
1.03
Div Yield
-
GMDA Company Profile
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
GMDA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| LXRX | Lexicon Pharmaceuticals, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| IOVA | Iovance Biotherapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| BLRX | BioLineRx Ltd. |
| MCRB | Seres Therapeutics, Inc. |
| ARDX | Ardelyx, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| IBRX | ImmunityBio, Inc. |
| INZY | Inozyme Pharma, Inc. |